SARS News and Research

RSS

“Sybodies” protect against SARS-CoV-2 in hamster model

Researchers in China, The Netherlands, France, and Switzerland have identified synthetic nanobodies or “sybodies” that exhibit potent neutralizing activity against severe acute respiratory syndrome coronavirus (SARS-CoV-2) – the agent responsible for the ongoing coronavirus disease 2019 (COVID-19) pandemic.

3 Aug 2021

PROTEIN-ID project aims to develop a device able to generate identity card of proteins

A device able to generate proteins identity card: this is the ambitious goal of the "PROTEIN ID" project, funded by the European Union with about 3 million euro for the next 3 years and coordinated by the IIT-Istituto Italiano di Tecnologia (Italian Institute of Technology).

3 Aug 2021

Study suggests second Pfizer-BioNTech vaccine shot may not be needed after previous SARS-CoV-2 infection

Researchers in Austria have conducted a study showing that individuals previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibit a significantly more pronounced antibody response to one dose of Pfizer-BioNTech’s coronavirus disease 2019 (COVID-19) vaccine than previously uninfected individuals.

3 Aug 2021

COVID-19 lockdowns had minimal impact on medical treatments for Australian cancer patients

Australian cancer patients kept up their pharmaceutical treatments during last year's COVID-19 lockdowns, a big data study from UNSW Sydney shows.

3 Aug 2021

How do Australians inform themselves about the COVID-19 pandemic?

A recent study in Australia indicates that public health communication is far from being the main source of information regarding the coronavirus disease 2019 (COVID-19) pandemic.

3 Aug 2021

SARS-CoV-2 Delta and Delta AY.1 variant show similar Covaxin-induced neutralization

A new study from India suggests that the Indian-made Covaxin whole-virus inactivated vaccine against the SARS-CoV-2 retains significant efficacy against the newer delta variants of the virus.

3 Aug 2021

Purifying selection drives time-dependency of short-term mutation rates in SARS-CoV-2 and pH1N1 influenza

A new paper, available on the medRxiv* preprint server, indicates the adaptation undergone by the SARS-CoV-2 molecular genome and the pH1N1 influenza pandemic strain during the first year of their spread, separately. Using statistical and phylogenetic skills, the researchers present a picture of the emergence, rates of change, and of growth, of these two viruses as time passes.

3 Aug 2021

Strategies to reduce SARS-CoV-2 infection risk from bioaerosol exposure during dental procedures

Limiting infection transmission is central to the safety of all in dentistry, particularly during the current SARS-CoV-2 pandemic, yet many dental procedures unavoidably generate aerosols.

3 Aug 2021

What is the potential of microphysiological systems in COVID-19 research?

In a recently published review article in the journal Drug Discovery Today, scientists have described the utility of human-based microphysiological systems MPSs in understanding the pathophysiology of SARS-CoV-2 infection and developing effective therapeutic interventions. Moreover, they have described the establishment of a global working group to synchronize recent developments around MPSs and COVID-19 research.

3 Aug 2021

Study conducts systematic review of the pre- and asymptomatic SARS-CoV-2 transmission

Researchers at Oxford University, UK, have conducted a systematic review of the available studies to address the role of presymptomatic and asymptomatic transmission of SARS-CoV-2.

3 Aug 2021

Study examines efficacy Pfizer-BioNTech vaccine among USAF Academy Cadets

A new study published on the medRxiv* preprint server has estimated the effectiveness of vaccines in preventing COVID-19 as a function of time since vaccination.

3 Aug 2021

Unvaccinated and vaccinated have similar viral load in communities high in SARS-CoV-2 delta

The findings reveal that vaccinated and unvaccinated individuals exhibit similar viral loads following delta infection and that vaccine breakthrough cases have the potential to transmit infection to others. The study is currently available on the medRxiv* preprint server.

3 Aug 2021

National Qatari study shows vaccination reduces risk of spreading SARS-CoV-2 infection

A team of scientists from Qatar and the United States has recently studied the viral transmission potential of individuals with primary severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, reinfection, or vaccine breakthrough infection.

2 Aug 2021

CDC scientists model the most efficient physical barrier against SARS-CoV-2 for worker protection

Size doesn’t matter — when it comes to physical barriers in the workplace. A new Centers for Disease Control and Prevention (CDC) study found larger barriers were not statistically better than smaller physical barriers in protecting against severe acute respiratory syndrome 2 (SARS-CoV-2).

2 Aug 2021

Study shows efficacy of Pfizer-BioNTech and Moderna vaccines against SARS-CoV-2 delta variant

Researchers in Singapore have conducted a study showing that the messenger RNA- (mRNA) based coronavirus disease 2019 (COVID-19) vaccines developed by Pfizer-BioNTech and Moderna are highly effective at protecting against symptomatic and severe disease following infection with the rapidly spreading B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

2 Aug 2021

New model can help clinicians to predict 40-day mortality risk in hospitalized COVID-19 patients

Researchers from Hackensack Meridian University Medical Center and Berry Consultants, LLC, Austin, Texas have developed a new model to help clinicians predict the risk of death within 40 days in patients who are hospitalized with COVID-19 infection.

2 Aug 2021

Pfizer moves towards an oral anti-COVID-19 therapy

Researchers in the United States have described a novel antiviral agent against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) currently being evaluated in clinical trials as a treatment for coronavirus disease 2019 (COVID-19).

2 Aug 2021

Existing drug may be effective in treating SARS-CoV-2

Scientists from the University of Chicago have found that the drug masitinib may be effective in treating COVID-19.

2 Aug 2021

Researchers discover titanium oxide nanoparticle that recognizes SARS-CoV-2’s non-structural protein 1

A pioneering study reports on the interaction of a tailored titanium oxide nanoparticle (NP) with the full-length SARS-CoV-2 non-structural protein 1 (nsp1). This should be of value in developing new therapeutic tools against coronaviruses that act by targeting their proteins. It could also help map the structure of activated proteins.

2 Aug 2021

Polyuridine sequence of mouse coronavirus can be targeted to prevent host cell death

A new study reports the use of a modified deoxyribonucleic acid (DNA) oligonucleotide that has a 3’ polyadenine (polyA) tail to bind to the 5’-polyU tract in the mouse coronavirus (MHV-A59). Treatment of mouse cells infected with MHV-A59 with this molecule led to a marked reduction in cell deaths.

2 Aug 2021

SARS News and Research

“Sybodies” protect against SARS-CoV-2 in hamster model

PROTEIN-ID project aims to develop a device able to generate identity card of proteins

Study suggests second Pfizer-BioNTech vaccine shot may not be needed after previous SARS-CoV-2 infection

COVID-19 lockdowns had minimal impact on medical treatments for Australian cancer patients

How do Australians inform themselves about the COVID-19 pandemic?

SARS-CoV-2 Delta and Delta AY.1 variant show similar Covaxin-induced neutralization

Purifying selection drives time-dependency of short-term mutation rates in SARS-CoV-2 and pH1N1 influenza

Strategies to reduce SARS-CoV-2 infection risk from bioaerosol exposure during dental procedures

What is the potential of microphysiological systems in COVID-19 research?

Study conducts systematic review of the pre- and asymptomatic SARS-CoV-2 transmission

Study examines efficacy Pfizer-BioNTech vaccine among USAF Academy Cadets

Unvaccinated and vaccinated have similar viral load in communities high in SARS-CoV-2 delta

National Qatari study shows vaccination reduces risk of spreading SARS-CoV-2 infection

CDC scientists model the most efficient physical barrier against SARS-CoV-2 for worker protection

Study shows efficacy of Pfizer-BioNTech and Moderna vaccines against SARS-CoV-2 delta variant

New model can help clinicians to predict 40-day mortality risk in hospitalized COVID-19 patients

Pfizer moves towards an oral anti-COVID-19 therapy

Existing drug may be effective in treating SARS-CoV-2

Researchers discover titanium oxide nanoparticle that recognizes SARS-CoV-2’s non-structural protein 1

Polyuridine sequence of mouse coronavirus can be targeted to prevent host cell death

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News